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Baclofen, particularly high-dose baclofen, has recently emerged as a treatment of major
interest for alcohol-dependence. However, baclofen has many potentially dangerous side
effects, and the maximal dose of baclofen that may be used is a matter of discussion. Here,
the author analyses the medical charts of the last 100 patients seen in his clinic, 17 of whom
have been taking a very high dose of baclofen, which is to say, more than 300 mg/day.The
analysis of the charts shows that the very high-doses baclofen were justified in almost all
the cases. Side effects are analyzed.
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INTRODUCTION
High-dose baclofen has been shown to produce a remarkable state
of indifference toward alcohol (1). However, the question of the
upper limit of baclofen dosage that may be reached is a matter of
discussion. Drug summaries recommend not exceeding the daily
dose of 75–80 mg (75–80 mg/day) (2, 3) although long-term stud-
ies have shown that doses exceeding 250 or 300 mg/day are often
necessary to produce a state of complete indifference to alcohol (4,
5). Recently, the French Health Safety Agency released a recom-
mendation allowing for the prescription of baclofen to be given
up to 300 mg/day, but not beyond, for the treatment of alcohol
dependence (French Ministerial decree of June 13, 2014).
The present report is an analysis of the author’s medical charts
of patients taking, or having taken, very high doses of baclofen,
i.e., more than 300 mg/day for the treatment of their alcohol
dependence. Since 2008, the author has prescribed baclofen to
approximately 600 alcohol-dependent patients. The charts of the
last 100 patients, followed for at least 6 months, were reviewed.
At the time of the review (July 2014), all the patients except one
(see Patient-14 below) were under the care of the author (last visit
posterior to May 2014). Among the 100 charts, it appeared that 17
patients have been taking doses of baclofen superior to 300 mg/day
at 1 time or another during their treatment (7 other patients
reached the dose of 300 mg/day without exceeding it). This means
that, according to this cohort, 17% of alcohol-dependent patients
need more than 300 mg/day of baclofen for their treatment (and
nearly one in four needs at least 300 mg/day).
The treatment was conducted similarly for all patients; doses
were progressively increased (one additional 10 mg-tablet every
3 days) until a state of indifference toward alcohol (suppression of
craving) was reached. After reaching a dose of 120–150 mg/day, if
these doses were ineffective, or not sufficiently effective, patients
were asked to actively participate in the dose increase. They were
told that, unless they have no unbearable side effects, they must
continue to increase the dose of baclofen, with no given limit of
dosage, as long as they have episodes of craving for alcohol. In
case of unbearable, or difficult to bear, side effects, they were told
to slow the progression of the increase, or to decrease the dose
until the side effect either disappears or becomes bearable, and
then once again increase the dose, possibly much more slowly (one
tablet, or a half-tablet, every week or 10 days, or possibly even more
slowly). Patients were thereby trained to manage by themselves the
increase of the doses according to a principle of self-involvement
in the management of their treatment, while always under strict
medical control (monthly visits, phone call to the author whenever
necessary).
BACKGROUND
In previous reports of clinical cases of baclofen in alcohol-
dependence patients were always treated with doses beneath
300 mg/day (1, 6–8).
CLINICAL CASES
Clinical cases are presented below (see also Table 1). Patients
are classified according the length of their follow-up, from the
longest to the shortest. Side effects will be considered in a separate
paragraph in the Section “Discussion.”
PATIENT-1
Patient-1 (Pt1) is a 58-year-old healthy farmer drinking approxi-
mately three or four bottles of wine per day (he denied drinking,
hiding bottles in the bush). He was brought in our clinic by his
family, and did not seem to be very motivated to stop drinking. He
was forced to take the baclofen treatment, given authoritatively by
his wife, and rapidly drank much less (at 120 mg/day), but nev-
ertheless continued to drink to excess (on the sly), as evidenced
by biological measures. He stopped drinking at 210 mg/day (nor-
malization of hepatic enzymes). After a year or two, he decided
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Table 1 | Digest of cases.
Patient Year of
birth
Gender Pretreatment
daily alcohol
consumption,
in grams
Number of
years of alcohol
dependence
before treatment
Baclofen starting
date (and duration
of treatment,
in months)
Maximal
baclofen
dose,
in mg
Duration of
dose over
300mg/day,
in months
Last visit
baclofen
dose,
in mg
Last visit alcohol
consumption,
in mg (and
stability)
Pt1 1950 M 240 20 17/12/2008 (67) 360 1 360 0 (Stable)
Pt2 1981 M 450 6 17/06/2009 (60) 320 3 300 20–30 (Stable)
Pt3 1951 F 240 6 25/03/2010 (51) 400 3 300 <10 (Stable)
Pt4 1978 M 350 10 18/05/2010 (49) 520 11 320 (Irregular) 0 (Most of time)
Pt5 1978 M 240 10 23/06/2010 (48) 400 2 250 (Irregular) 120 (Irregular)
Pt6 1972 F 310 3 03/11/2010 (44) 330 9 330 0 (Stable)
Pt7 1981 M 380 12 17/08/2011 (39) 320 8 300 150 (Weekend only)
Pt8 1967 M 280 22 19/08/2011 (39) 420 5 400 20 (Stable)
Pt9 1969 M 320 15 11/01/2012 (26) 440 22 390 20 (Stable)
Pt10 1955 M 180 10 05/12/2012 (19) 360 1.5 360 50 (Irregular)
Pt11 1961 M 280 20 09/01/2013 (18) 420 13 300 60 (Stable)
Pt12 1963 M 350 15 12/04/2013 (14) 320 1 320 120 (Most of time)
Pt13 1976 M 180 8 03/09/2013 (10) 350 1.5 200 0 (Stable)
Pt14 1975 M 230 3 12/11/2013 (6) 630 1.5 630 0 (But relapsed)
Pt15 1984 M 350 5 02/12/2013 (7) 400 2.5 320 (Irregular) 0 (Most of time)
Pt16 1972 M 200 10 18/12/2013 (7) 310 0.5 290 30 (Irregular)
Pt17 1982 M 240 6 20/12/2013 (7) 310 2 310 0 (Stable)
he was cured, stopped baclofen, and relapsed a few months later.
Baclofen was restarted but the dose of 210 mg was insufficient.
Doses were then increased (in large part driven by his daugh-
ter who was a pharmacist) and he was taking 360 mg/day at the
time of his last visit (June 2014). According to the family, he has
no craving at all, not drinking even when he is offered a glass
of wine.
PATIENT-2
Patient-2 (Pt2) is a 28-year-old salesman drinking one to two
bottles of whiskey per day (4–8 20 cc whiskey flasks), and a vari-
able number of beers. He is emotionally very unstable, impulsive,
abuses cannabis, and has a long history of anxiety and depres-
sion for which he has previously been treated but he was tak-
ing no psychotropic medications (except benzodiazepines) when
baclofen was started. The road to abstinence with baclofen turned
out to be very long and chaotic, with nearly 4 years of ups and
downs. Baclofen was initially very effective; he stopped drink-
ing completely at 120 mg/day but started drinking again after
a month or two, beer only. He later turned to sparkling wine
for several months. He alternated periods of sobriety, periods
of moderate drinking (one bottle of sparkling wine or some
beer) and short episodes of massive drinking during the fol-
lowing years. He acknowledged that baclofen greatly reduces his
craving, and he has progressively increased it over the years,
reaching the dose of 320 mg during some months in 2013.
But his daily treatment compliance was irregular (often off-
schedule). He is now (June 2014) taking 300 mg/day regularly,
he says, and drinks an average of two or three beers per day.
He is still impulsive and equally emotionally unstable and is still
cannabis-dependent (although his consumption of cannabis has
substantially decreased).
PATIENT-3
Patient-3 (Pt3) is 59-year-old woman referred for an intractable
alcoholism (4 bottles of white wine per day) associated with a
fronto-temporal dementia. The dementia was labeled idiopathic
by her neurologist, independent of the alcoholism. She is treated
by clomipramine and donepezil. Baclofen was considered by the
family as a last-resort attempt. Increasing baclofen doses proved
to be extremely difficult due to the massive memory problems of
the patient and to insufficient surveillance of treatment admin-
istration by the (very busy) family. It took 2 years to reach the
dose of 400 mg/day (thanks to an ancillary worker who was hired
by the family to accompany the patient and control her treat-
ment observance). At that dose, the patient suddenly stopped
drinking, showing a total indifference toward alcohol. Two years
later, she is still sober (ritually filling at dinner time a glass of
wine, which she does not finish), and has recovered fairly good
memory capacities (the diagnosis of idiopathic dementia has been
abandoned).
PATIENT-4
Patient-4 (Pt4) is 32-year-old technician drinking one bottle of
rum every day. He suffers from a severe anxiety disorder, with
agoraphobia and emotional instability (treated with an antidepres-
sant and an atypical antipsychotic). He became almost completely
abstinent at 200 mg/day (although not completely indifferent to
alcohol), but had episodes of relapse due to stress and instabil-
ity (mainly in relation to conflicts in the workplace, a divorce
and concomitant painful somatic illness). He shifted from rum
to beer, and increased baclofen doses at each relapse, reaching
the dose of 520 mg/day. He is presently stabilized at 320 mg/day,
does not drink and says he has no craving, although still having
brief episodes of massive alcoholization (an average of one every
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2 months), when he drinks an entire bottle of rum and/or other
drinks over 1 or 2 days.
PATIENT-5
Patient-5 (Pt5) is 32-year-old unemployed artist-painter drink-
ing an average of three bottles of wine and 1 l of beer per day.
He has a long history of untreated anxiety and depression. He
takes no medications except occasional benzodiazepines. Alcohol
has an obvious anxiolytic and antidepressant function for him,
and his real desire to stop drinking was questionable when he
started baclofen. His craving for alcohol and alcohol consump-
tion significantly decreased (one bottle of wine, no more beer) at
a relatively low dose of baclofen (150 mg/day). However, partly
due to stressful life events, he progressively relapsed and slowly
resumed his previous drinking habits, taking less and less baclofen
until a complete stop that lasted several months. He then restarted
baclofen, acknowledging that although baclofen greatly decreases
his craving, it is, however, ineffective in completely suppressing his
compulsive rituals in drinking. He slowly and irregularly increased
baclofen up to 400 mg/day, remaining at that dose for approxi-
mately 2 months, still drinking to excess (one to two bottles of
wine per day), after what he decreased the dose of baclofen down to
250 mg/day, which he is still taking, not very regularly, still drinking
an average of 1.5 bottle per day.
PATIENT-6
Patient-6 (Pt6) is a 38-year-old Human Resources assistant drink-
ing half a bottle of gin and a bottle of wine every day. She is healthy
and takes no medications. She stopped drinking at the dose of
240 mg/day of baclofen. But 2–3 months later, she started to drink
moderate doses of alcohol again and increased the baclofen dose
to 270 mg/day. She remained 2.5 years taking this dose very reg-
ularly and was almost always sober, but she had more and more
often moments of craving when coming home from work in the
evening and got into a habit of adding three more tablets to the
evening dose, and after a while she added another three tablets.
She is now taking baclofen 330 mg/day, very regularly. She is sober
and has no craving.
PATIENT-7
Patient-7 (Pt7) is a 30-year-old commercial employee drinking
one or more bottle of rum every day. He suffers from panic attacks
(no treatment, except benzodiazepines). He immediately appreci-
ated baclofen, finding that it gave him a feeling of euphoria with
a marked decrease in anxiety. He rapidly stopped drinking during
the week but continued to drink with friends during the weekend.
After a few months, while he was regularly taking 200 mg/day, he
started drinking again,as before,during the week. He then progres-
sively increased baclofen up to 400 mg/day and stopped drinking
during the week though continuing to drink during the weekend
(more as a routine than because of a craving). He is now stabilized
at 300 mg/day, does not drink during week days (no craving), but
still drinks during the weekend (a bottle of rum or whiskey for
the 2 days), and often decreases the dose of baclofen during the
weekend “to facilitate drinking” he says. (The decrease of baclofen
is often accompanied by a baclofen withdrawal syndrome, marked
by sweats, anxiety, shaking, and itching – an unusual syndrome
during baclofen partial withdrawal).
PATIENT-8
Patient-8 (Pt8) is a 44-year-old city hall employee, drinking an
average of 5 l of beer every day and a variable quantity of wine.
He has a long history of depression and suicide attempts, detox
cures and psychotropic treatments. At the beginning of baclofen
treatment, he was taking an antidepressant and several anxiolytics.
Baclofen dose increase was slowed by the occurrence of many diffi-
cult to bear side effects. He started decreasing alcohol consumption
at 200 mg/day. At 250 mg/day, he had almost no more craving,
but continued compulsively to drink during what he called his
“evening rituals”: one beer and two to four glasses of wine. This
“ritual” consumption lasted 18 months, during which the patient
was regularly taking 250 mg/day of baclofen after which, following
certain life events, he decided to stop drinking completely, and on
his own initiative increased baclofen to this end. He reached the
dose of 420 mg/day, at which he stopped drinking completely. He
then decreased the dose to 400 mg/day and is still at that dose in
July 2014, still sober.
PATIENT-9
Patient-9 (Pt9) is a 43-year-old invalid man, drinking one bottle
of whiskey per day, always in the evening. He has a history of bipo-
lar disorder (treated by depakine+ olanzapine+ escitalopram+
several benzodiazepines), and is a former cocaine and cannabis
addict. Baclofen was progressively increased up to 300 mg/day
without any effect. Above this dose, Pt9 began to progressively
decrease drinking and to change his drinking habits, shifting from
whiskey to rosé wine, which he began at noon. At 350 mg/day he
drank an average of 1.5 bottle of wine, at 440 mg/day a half bot-
tle, and at 480 mg/day (eleventh month of treatment), only two
glasses. Seven months later, he was still taking 480 mg/day, was
sober, but said he still has frequent episodes of craving. He never-
theless started to decrease the dose of baclofen and, at 200 mg/day,
had a long period of relapse for which he needed to be hospital-
ized. After that, he again increased baclofen progressively, up to
400 mg/day. He now takes 390 mg/day (June 2014), and drinks an
average of two glasses of wine per day. He feels very well, and plans
to take up volunteer work.
PATIENT-10
Patient-10 (Pt10) is a 57-year-old pharmacy technician drinking
three bottles of wine per day. He is in good health and takes no
medications. The dose of baclofen was progressively increased up
to 320 mg/day over 7 months, without incident, and the consump-
tion of alcohol decreased by more than two thirds (daily amount
between ½ and 1 bottle per day), with a craving notably reduced
but still present. The length of treatment, 7 months, is probably
insufficient, and it is expected that a further dose increase will
allow the achievement of a complete suppression of craving.
PATIENT-11
Patient-11 (Pt11) is a 52-year-old bricklayer (on sick leave for
the last 2 years) drinking 4–5 l of beer (7.5°) per day. He is also
a cannabis addict and suffers from depression (taking paroxe-
tine over the last 5 years). His craving was almost completely
suppressed at 200 mg/day but there remained strong rituals of
drinking that made him continue to drink despite an obvious lack
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of interest for alcohol. He spontaneously increased progressively
the doses up to 420 mg, and stopped drinking completely at that
dose, but his personal attending physician told him that the dose
was too high and potentially dangerous (despite an almost com-
plete absence of side effects) and so he decreased the dose. He is
now taking 300 mg/day and drinks an average of 1 l of beer per
day. He returned to work and takes no more paroxetine.
PATIENT-12
Patient-12 (Pt12) is a 50-year-old insurance employee drinking a
bottle of pastis (a 45° beverage close relative of absinth) every day.
He is in good health and takes no medications. Baclofen increase
proved to be very difficult because of the occurrence of a num-
ber of unbearable side effects at relatively low doses of treatment.
He nevertheless very courageously surmounted these effects and
slowly increased the doses. The nature of side effects changed at
higher doses (from delirium and serious behavioral disturbances
to slowness, bizarre somatic sensations, sweating, and insomnia).
The first sign of a decrease in drinking (280 mg/day) was that he
began to drink more and more slowly, keeping the beverage sev-
eral minutes in the mouth before swallowing (this is a rare, but
not exceptional, effect of baclofen in alcoholics). He progressively
decreased alcohol consumption but did not stop it, being strongly
and compulsively attached to his evening drinking habits. The
alcohol consumption nevertheless decreased with the increase of
baclofen. At the last visit, the dose was 320 mg/day. He was still
drinking approximately the third of a bottle of pastis every day,
and he planned to continue to increase baclofen. Bromazepam
was added to his treatment in August 2013, for insomnia, which
he is still taking (and which is a great help).
PATIENT-13
Patient-13 (Pt13) is a 37-year-old supermarket manager drinking
half a bottle of whiskey per day. He is in good health. Baclofen
progressive increase was very slow due to the occurrence of
many uncomfortable side effects. Baclofen was increased up to
300 mg/day without any effect on alcohol consumption or crav-
ing. Suppression of craving and alcohol consumption occurred
abruptly at 350 mg/day. Pt13 takes all baclofen tablets at once in
the morning before going to work (a very unusual way of pro-
ceeding, but Pt13 found this was the best for him). He took this
dose for a month or two, then decreased it to 300 mg, then to
200 mg/day. In July 2014, he had no craving, was totally abstinent
but progressively developed a worrying depression over the last
months. Whereas he was taking no medication when baclofen was
started, he is now taking escitalopram, alprazolam, and zopiclone.
PATIENT-14
Patient-14 (Pt14) is a 38-year-old salesman (unemployed) drink-
ing an average of 5 l of beer per day. He drinks a little during the day
but drinks massively at evening and night-time, away from home,
with friends, compulsively until totally drunk. His wife is threat-
ening him with divorce. He is very impulsive, suffers from a major
anxiety disorder, and takes no medication. He increased progres-
sively baclofen, and began to decrease drinking at 250 mg/day.
At 360 mg/day (fourth month of treatment), he was not drinking
more than two or three cans of beer. He suddenly decided (without
medical advice) to increase baclofen rapidly until he reaches total
abstinence. Total abstinence occurred at the dose of 630 mg/day.
He remained at this dose for 1.5 months, despite medical injunc-
tions to decrease the dose. He found a job and seemed extremely
satisfied: “my wife is happy,” “my life has completely changed.” At
the end of May 2014, he showed signs of an acute delirium, with
agitation in the street and a facial hematoma, and was transported
to an intensive care unit by a police emergency squad. He regained
consciousness a few hours later, and left the unit against medical
advice <24 h after admission. He has given no news since despite
many attempts to reach him. He very likely stopped baclofen.
PATIENT-15
Patient-15 (Pt15) is a 29-year-old successful business manager
drinking one bottle of whiskey per day, and often some other
drinks. He is healthy and takes no medications. Detox cures
and usual medications were ineffective. He escalated doses more
rapidly than planned, became indifferent to alcohol at 250 mg/day,
but deliberately increased the dose up to 400 mg/day (“to be on the
safe side”he said),and then decreased the dose,maintaining it most
often around 320 mg, sometimes higher (in case of stress), some-
times much lower (when he decides to “live it up” with friends).
He is almost always sober and has no craving. This case is a typical
case of successful self-management of the treatment.
PATIENT-16
Patient-16 (Pt16) is a 41-year-old salesman in a fashion boutique,
drinking mostly beer (an average of 3 l/day), but also any kind
of alcohol when accessible. He is also cannabis dependent, and
occasionally takes cocaine. He is impulsive, very unstable emo-
tionally, and often has severe fits of anger and aggressiveness. He
appeared to be unable to increase progressively and regularly the
doses of baclofen as prescribed. He increased baclofen very rapidly
to 270 mg/day (“as Olivier Ameisen did” he said), then decreased
it rapidly, increased once again the doses, reaching 310 mg/day for
a short while. He says that baclofen has a stimulant effect on him,
and makes him feel more placid and less aggressive. He some-
times seems to take baclofen as if it were a drug of abuse, but he
also says that alprazolam or hypnotics make him “feel high.” After
6 months of more or less chaotic, but constant, baclofen treat-
ment, he appears to have almost no craving for alcohol, drinks
rarely (only when driven by friends), has substantially decreased
cannabis, and has started a treatment for his tobacco dependence.
PATIENT-17
Patient-17 (Pt17) is a 31-year-old engineer drinking an average
of 60 cc of whiskey or vodka per day. He suffers from depression
(treated with paroxetine). Drinking progressively decreased with
the increase of baclofen. He reached a complete suppression of
craving at 310 mg/day. He had a brief relapse 2 months ago (sud-
den compulsive drinking of a flask of vodka, for no particular
reason), and is totally sober since.
DISCUSSION
This retrospective analysis of medical charts shows that a substan-
tial number of alcohol-dependent patients treated with baclofen
need treatment doses superior to 300 mg/day (17% of the 100
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cases). It is clear that if the doses of baclofen had been limited to
300 mg/day as recently recommended by the French Health Safety
Agency, these patients would not have fully benefited from the
craving–suppressing effects of baclofen.
The clinical vignettes show that the use of high-dose baclofen
took place in many different contexts and situations, some-
times potentially inappropriate [family pressure (Pt1), or patient’s
impulsivity (Pt14)], but in most cases the high-dose treatment was
justified, resulting in very positive effects.
Side-effects occurred in all the patients except Pt4, who always
denied any side effect (which one may doubt). Side effects were
in general minor and benign. Almost all patients reported fatigue
and/or insomnia. Insomnia was sometimes severe. Most of the
patients had insomnia before baclofen, but baclofen itself induced
or worsened insomnia in many of them (baclofen-induced insom-
nia was often improved by hypnotics but not always, however).
Other benign side effects were nausea, dizziness, headache, pain
in muscles and joints, motor instability, feeling of head crushing,
feelings of electric discharges, decrease in vision, decrease in libido,
aggressiveness, transient hypomania, paresthesias, tinnitus, sweats,
cramps, spasms, dry throat. There were four cases of severe side
effects: Pt8 was suffering from somnambulism (and falls during
sleepwalking) long before treatment, but baclofen worsened his
somnambulism, which became associated with nocturnal delir-
ium, and 1 day Pt8 fell during an episode of sleepwalking and
broke his ankle (at that time, baclofen dose was 370 mg/day, and
he was drinking about 50 g of alcohol per day). Pt12 had a period
of nocturnal delirium associated with bizarre stereotyped behav-
ior during the day, and 1 day he woke up with paralyzed legs. The
emergency physician suspected a stroke and he was hospitalized,
but stood up normally a few hours later. All the investigations (car-
diovascular, brain imaging) were normal (at that time, baclofen
dose was 210 mg/day, and he was drinking more than 300 g of
alcohol per day). Pt13 progressively developed a depressive state,
which, although Pt13 has no suicidal thoughts, could be consid-
ered as a serious side effect (the direct relationship with baclofen
is, however, disputable). Pt14, as described in the clinical vignette,
took an unreasonable amount of baclofen, and 1 day presented a
state of confusion and a facial hematoma and was hospitalized in
an intensive care unit for that, but the precise circumstances of this
severe side effect have not been elucidated.
CONCLUDING REMARKS
Baclofen treatment is for many alcoholic patients a long story and
a long fight. The fight involves both the patient and the physician,
and the notion of therapeutic alliance finds here all its meaning,
as it is essential that the patient participates in the managing of
the treatment under the control of the physician. To be effective,
baclofen may need to be given at high or very high doses. An
imposed limit to the dose of baclofen is a loss of the opportunity of
being cured for many patients. Baclofen is not more dangerous at
high doses than at low doses when the treatment is well supervised
by the physician. Side effects, even severe side effects, can occur at
any dose. Most of the time, difficult to bear side effects present at
low doses will vanish or change in nature when the baclofen dose
is increased. Therefore, on the condition of a good therapeutic
alliance between the patient and the physician, baclofen should be
prescribed with no imposed upper limit of dosage.
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